Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market ...

UiPath reported quarterly earnings of nine cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue of $424 million missed the analyst consensus estimate of $425.36 ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a ...

Ratings for AnaptysBio (NASDAQ:ANAB) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ANAB: AnaptysBio NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended ...